Funding And Cash RunwayTheriva has a cash runway into the fourth quarter of 2025, supported by an additional $7.5 million raised from equity financing.
Future Clinical DevelopmentsTheriva has begun planning a pivotal P3 study to evaluate the same combo of VCN-01 + gem/nab vs. gem/nab alone in metastatic PDAC, with plans to request an End-of-Phase 2 meeting with the FDA to discuss the proposed design.
Market TrendsThe oncolytic virus space has been gaining traction with investors and is poised for an active period, with Theriva's VCN-01 approach being differentiated and having orphan drug and fast track designations for pancreatic cancer.